A phase Ia/Ib, single-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of PIKA rabies vaccine (Vero cell) for human use, freeze-dried in healthy adult subjects
Latest Information Update: 21 Aug 2024
At a glance
- Drugs Rabies vaccine Yisheng Biopharma (Primary)
- Indications Rabies
- Focus Adverse reactions; Pharmacodynamics
- 15 Aug 2024 According to LakeShore Biopharma media release, In 2023, the Company completed the Phase I clinical trial of PIKA YS-ON-001 in China.
- 15 Aug 2024 Status changed from recruiting to completed, according to LakeShore Biopharma media release.
- 24 May 2024 According to a YS Biopharma media release, YS Biopharma company name changed to LakeShore Biopharma.